Abstract: Methods, compositions and kits are disclosed. The compositions are light emitting and comprise a polymeric matrix having dissolved therein a photoactive compound. The composition has the characteristic that, after activation of the photoactive compound, the rate of decrease in the intensity of light emission at any time during a 20-fold decrease in the intensity is proportional to the intensity of the light emission. In one embodiment the polymeric matrix is comprised of particles of about 20 nm to about 100 &mgr;m in diameter to which is bound a specific binding pair member. The particles generally comprise a polymeric matrix having dissolved therein about 1 to about 20% by weight of a dopant. The compositions may be used in methods for determining an analyte. A combination is provided comprising (1) a medium suspected of containing the analyte, (2) and the aforementioned composition.
Type:
Grant
Filed:
December 15, 1999
Date of Patent:
March 9, 2004
Assignee:
Dade Behring Marburg GmbH
Inventors:
Sharat Singh, John S. Pease, Jacqueline Sadakian, Daniel B. Wagner, Edwin F. Ullman
Abstract: Compositions are disclosed comprising (a) a metal chelate wherein the metal is selected from the group consisting of europium, terbium, dysprosium, samarium osmium and ruthenium in at least a hexacoordinated state and (b) a compound having a double bond substituted with two aryl groups, an oxygen atom and an atom selected from the group consisting of oxygen, sulfur and nitrogen wherein one of the aryl groups is electron donating with respect to the other. Such composition is preferably incorporated in a latex particulate material. Methods and kits are also disclosed for determining an analyte in a medium suspected of containing the analyte. The methods and kits employ as one component a composition as described above.
Abstract: The present invention relates to an in vitro diagnostic method for patients with suspected deep venous thrombosis wherein by combined testing of patients' samples for D-dimer and CRP both the sensitivity and the negative predictive value of DVT diagnostics can be increased up to 100%.
Abstract: The present invention relates to antibodies which, in agueous solution, selectively bind to a transferrin-homologous carbohydrate deficient transferrin (CDT) without the latter needing to be bound to a solid phase. CDT is characterized by at least one of the two oligosaccharide chains which are normally bound to Asn 413 and/or Asn 611 of transferrin being entirely or substantially entirely lacking.
Abstract: The application relates to a method for determining the anticoagulatory potential of a sample by adding thrombomodulin and thromboplastin in a coagulation test.
Abstract: The present invention relates to procedures for the detection or for the determination of solid phase-associated factors, which are multiply associated with the same solid phase. According to the invention, the sample is brought into contact with a transmitter particle, on which at least one ligand having binding affinity for a solid phase-associated factor and a transmitter are immobilized, and a receiver particle, on which at least one ligand having binding affinity for said solid phase-associated factor and a receiver is immobilized, and then the signal is determined which results when transmitter and receiver are brought sufficiently close to one another. In particular, the invention relates to the detection of cell surface receptors which can be used for the typing of cells or for the determination of cell activation states. It is thus possible to replace the hitherto widely customary flow cytometry by a more simple procedure.
Type:
Grant
Filed:
December 18, 1998
Date of Patent:
October 14, 2003
Assignee:
Dade Behring Marburg GmbH
Inventors:
Michael Kraus, Carsten Schelp, Wilhelm Schuy
Abstract: An immunochemical method for the determination of antibodies which are specific for an antigen and are of one of the immunoglobulin classes: A, M, D or E in a fluid, with this fluid being contacted with a solid phase to which the antibodies against this immunoglobulin class, or a fragment of an antibody of this type, are bound, which results in the immunoglobulin of this class being bound to this solid phase, and this solid phase being contacted with the antigen, which carries a labeling means where appropriate, and with a labeled antibody or a labeled fragment of an antibody against the antigen if the antigen is unlabeled and determination, from the amount of labeling means which is bound to the solid phase, of the amount of these antibodies which are specific for an antigen and are one of the immunoglobulin classes, which comprises the solid phase being simultaneously in contact with the fluid containing the antibody which is to be determined and with the antigen, which is labeled where appropriate, there b
Abstract: The invention relates to human procalcitonin and the preparation and use thereof. In particular, a process for preparing human procalcitonin is described wherein a gene coding for a polypeptide comprising the amino acid sequence of human procalcitonin is inserted into a vector; a host organism is transformed with this gene-containing vector; and the polypeptide expressed by the host organism is isolated. Furthermore the use of the polypeptides according to the invention, in particular as medicaments and diagnostic agents is described.
Abstract: The present invention relates to a ready-to-use ristocetin cofactor test reagent possessing long-term stability for use in coagulation tests.
Abstract: The invention relates to seroreactive regions on proteins E1 and E2 of human papillomavirus (HPV) 16. The application also relates to a vaccine which contains such peptides which contain the seroreactive regions. The invention likewise embraces compositions for diagnostic purposes which contain peptides with the seroreactive regions.
Abstract: Novel activated peptides and conjugates thereof, useful in diagnostic assays and therapeutics, and processes for the preparation thereof are disclosed.
Abstract: The invention relates to anti-procalcitonin antibodies, their preparation and use, in particular in therapy and diagnostics. The antibodies comprise binding to procalcitonin but not to free calcitonin, free katacalcin and free N-procalcitonin.
Abstract: The invention relates to synthetic peptides which have amino acid sequences which correspond, in whole or in part, to the amino acid sequence of prothrombin and are antigenic, to the use thereof for the immunization of an animal and for the purification of specific antibodies, to antibodies against these peptides, and to the use of the antibodies for the determination of the fragments F2/F1+2.
Abstract: The present invention relates to an immunodeficiency virus of drill monkeys, its RNA, the corresponding cDNA, proteins derived therefrom and fragments of the nucleic acids or proteins. The invention likewise relates to the diagnostic use of the nucleic acids and proteins mentioned and their fragments and to a diagnostic.
Type:
Grant
Filed:
July 26, 2000
Date of Patent:
May 20, 2003
Assignee:
Dade Behring Marburg GmbH
Inventors:
Lutz Gerhard Guertler, Hans Peter Hauser, Yvette Beatrice Dongmo Deloko, Leopold Zekeng, Lazare Kaptue
Abstract: The invention relates to human procalcitonin and the preparation and use thereof. In particular, a process for preparing human procalcitonin is described wherein a gene coding for a polypeptide comprising the amino acid sequence of human procalcitonin is inserted into a vector; a host organism is transformed with this gene-containing vector; and the polypeptide expressed by the host organism is isolated. Furthermore the use of the polypeptides according to the invention, in particular as medicaments and diagnostic agents is described.
Abstract: A method is disclosed for detecting the presence of a difference between two related nucleic acid sequences. In the method a complex is formed comprising both strands of each sequence. Each member of at least one pair of non-complementary strands within the complex have labels. The association of the labels as part of the complex is determined as an indication of the presence of a difference between the two related sequences. The complex generally comprises a Holliday junction. In one aspect a medium suspected of containing said two related nucleic acid sequences is treated to provide partial duplexes having non-complementary tailed portions at one end. The double stranded portions of the partial duplexes are identical except for said difference.
Type:
Grant
Filed:
December 7, 2000
Date of Patent:
April 29, 2003
Assignee:
Dade Behring Marburg GmbH
Inventors:
Alla Lishanski, Nurith Kurn, Edwin F. Ullman
Abstract: A novel immunodeficiency virus is disclosed which has the designation MVP-5180/91 and which has been deposited with the European Collection of Animal Cell Cultures (ECACC) under No. V 920 52 318. The characteristic antigens which can be obtained from it and which can be employed for detecting antibodies against retroviruses which are associated with immunodeficiency diseases are also disclosed, as are the DNA and amino acid sequences of the virus.
Type:
Grant
Filed:
June 22, 2001
Date of Patent:
April 22, 2003
Assignee:
Dade Behring Marburg GmbH
Inventors:
Lutz G. Guertler, Josef Eberle, Albrecht v. Brunn, Stefan Knapp, Hans-Peter Hauser
Abstract: A novel HIV type O immunodeficiency virus is disclosed which has the designation MVP-2901/94 and which has been deposited with the European Collection of Animal Cell Cultures (ECACC) under No. V 950121601. The characteristic antigens which can be obtained from the virus and which can be employed for detecting antibodies against retroviruses which are associated with immunodeficiency diseases are also disclosed, as are the partial DNA and amino acid sequences of the virus.
Type:
Grant
Filed:
July 6, 2000
Date of Patent:
April 15, 2003
Assignee:
Dade Behring Marburg GmbH
Inventors:
Hans-Peter Hauser, Stefan Knapp, Stefan Brust, Lutz G. Gürtler, Josef Eberle, Lazare Kaptue, Léopold Achengui Zekeng
Abstract: The invention relates to synthetic peptides which have amino acid sequences which correspond, in whole or in part, to the amino acid sequence of prothrombin and are antigenic, to the use thereof for the immunization of an animal and for the purification of specific antibodies, to antibodies against these peptides, and to the use of the antibodies for the determination of the fragments F2/F1+2. The antibodies hitherto used for the determination of the content of the fragments F2/F1+2 have been induced by immunization with natural, highly purified prothrombin fragments F2/F1+2. The isolation of these prothrombin fragments is elaborate and costly, and the antibodies generated therewith show cross-reactions with intact prothrombin. Used for the immunization according to the invention are synthetic peptides which have amino acid sequences which correspond, in whole or in part, to the amino acid sequence of prothrombin and are antigenic.